Vasculitis & polymyalgia rheumatica
A systematic review of patient-reported outcome measures in patients with anti-neutrophil cytoplasmic antibody associated vasculitis
An erratum to this article was published (Rheumatology (Oxford), 5 Mar 2026 ↗)
Authors' conclusion
Generic PROMs are useful in measuring significant changes but lack sensitivity to specific symptoms and unique AAV-related issues, while existing disease-specific PROMs have some limitations and may not fully capture the AAV patient's perspective on disease and treatment burden.
Study context
- Population
- People with ANCA-associated vasculitis (AAV) in studies using patient reported outcome measures (PROMs) (incl. Health-related quality of life (HRQoL)) as a primary or secondary outcome, literature up to July 2023
- Participants
- 30 articles
- Outcome
- PROM tools used in AAV
Methodological detailsquality assessed using the Critical Appraisal Skills Programme
- Quality assessed using the Critical Appraisal Skills Programme
Pooled result
As reported in the abstract
Different PROM tools used
22
Studies using SF-36 or a variation as generic measure of health status and/or HRQoL
76.7%
n = 23
Studies developing a disease-specific PROM
2
Further pooled results
- Studies showing no meaningful relationships between SF-36 and BVAS, VDI or disease duration
- 86.6%
- Neurological and sinonasal involvement, women and younger patients associated with poorer HRQoL
- Depression and anxiety common; socioeconomic factors such as unemployment significantly associated with poorer mental health outcomes
- GC independently associated with worse SF-36 scores
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →